Skip to main content
/ Amsterdam UMC

Studies van Amsterdam UMC

In het studieoverzicht zijn de studies gerubriceerd naar de volgende stadia: vroeg-, lokaal gevorderd- en gevorderd stadium. Daarnaast ie gekozen voor een indeling in niet kleincellig longkanker, kleincellig longkanker en overige thoracale tumoren/studies.

Vragen over een studie?

Contact opnemen

NSCLC

ITHACA

A clinical imaging study on cardiovascular complications of immune checkpoint inhibitors (ICI) using coronary angiography to investigate plaque progression after initiation of ICI

TROPION-LUNG08

A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS ≥50%) NSCLC Without Actionable Genomic Alterations (Tropion-Lung08) (Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)

DRUP

3rd line and beyond
Targeted Therapy

The Drug Rediscovery Protocol. A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers With a Known Molecular Prof

TAS6417-301

1st line
Immunotherapy

Randomized, Controlled, Open-label, Phase 3, Global Multi-Center Trial to Assess the Efficacy and Safety of Zipalertinib plus Chemotherapy versus Chemotherapy alone in Non-Small Cell Lung Cancer

GO41596

Immunotherapy

A Phase Ia/Ib, Open-Label, Multicenter, Global, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XmAb24306 as a Single Agent and in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors

DIRECT

1st line
Immunotherapy, radiotherapy and surger

Dual-immunotherapy and short-course medium-dose radiotherapy, followed by surgery for tumor microenvironment modification in early stage NSCLC: the DIRECT-trial.

ATTAIN

1st line
Imaging

A clinical imaging study using [18F]F-AraG PET to visualize Tumor infiltrating T-cell Activation in Non-small cell lung cancer

PACIFIC-4

1st line
Immunotherapy

A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515).

TAS6417-301

1st line
Immunotherapy

Randomized, Controlled, Open-label, Phase 3, Global Multi-Center Trial to Assess the Efficacy and Safety of Zipalertinib plus Chemotherapy versus Chemotherapy alone in Non-Small Cell Lung Cancer

ATTAIN

1st line
Imaging

A clinical imaging study using [18F]F-AraG PET to visualize Tumor infiltrating T-cell Activation in Non-small cell lung cancer

Brigatinib-PASS

3rd line and beyond
Targeted Therapy

A Cohort Study to Describe the Occurrence of Early-Onset Pulmonary Events in Patients with Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Treated with Brigatinib: A Post-Authorisation Safety Study

MARIPOSA-2

2nd and 3rd line
Targeted therapy, immunotherapy, chemotherapy

A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure

SHARP

1st and beyond
Imaging

A clinical imaging Study of the changes in [18F]F-AraG uptake following anti-PD-1 therapy in Non-small cell lung cancer.

POTENTIA

Phase 1
Immunotherapy

A Phase 1 Open-Label, Dose Escalation and Expansion Trial to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of CB307, a Trispecific Humabody® T-cell Enhancer, in Patients with PSMA+ Advanced and/or Metastatic Solid Tumours

STING

Phase 1
Immunotherapy

Phase I First Time in Human, open label PET imaging study to investigate the activation of T lymphocytes as well as biodistribution and tumor uptake of GSK3745417 administered to participants with advanced solid tumors

MIRATI KRYSTAL 12

3rd line and beyond
Targeted Therapy

A Randomized Phase 3 Study of MRTX849versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation

GCT1046-04

2nd line and beyond
Immunotherapy

A Safety and Efficacy Trial of GEN1046 as Monotherapy and in Combination With Pembrolizumab in Subjects With Recurrent Non-Small Cell Lung Cancer

ADAPT/ALEC

3rd line and beyond
Targeted Therapy

A prospective randomized controlled trial comparing standard treatment with ALK inhibitor alectinib to dose adjusted alectinib based on therapeutic drug monitoring

CD137/FAP

Phase 1
Immunotherapy

An open label, phase I PET imaging study to investigate the bio- distribution and tumor uptake of [89Zr]Zr-BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers

TRIDENT-1 (AvL)

All lines
Targeted therapy

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 (Repotrectinib) in Patients With Advanced Solid Tumors Harboring ROS1, or NTRK1-3 Rearrangements

DESTINY-Lung04

1st line
Targeted therapy, chenotherapy

An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations

ML41176-BIO (AvL)

2nd line and beyond
Targeted therapy

Unraveling tumor response and resistance to combined chemotherapy and PD-L1 inhibition with minimal invasive techniques in patients with advanced NSCLC with targetable disease

COMBINATION

1st line
TKI and chemotherapy

Combining afatinib and concurrent chemotherapy, followed by osimertinib and concurrent chemotherapy, in untreated EGFR positive NSCLC tumors.

ORCHARD

1st line
Immunotherapy

A Biomarker-Directed Phase 2 Platform Study in Patients with Advanced Non-Small Cell Lung Cancer whose Disease has Progressed on First-Line Osimertinib Therapy (ORCHARD)

PAULIEN

1st line
Immunotherapy

Pembrolizumab alone versus pembrolizumab-chemotherapy in first line NSCLC

PD-L1 PET (AvL)

Diagnostic
Imaging study

18 F-PD-L1 PET/CT to predict response to nivolumab in patients with NSCLC

Early stage SBRT-immuno

1st line
Immunotherapy

Combining SBRT and immunotherapy in early stage NSCLC patients planned for surgery: exploring safety and immunological proof of principle.

Osiris

1st line
Immunotherapy

Osimertinib resistance analysis in patients with EGFR mutation positive non-small-cell lung carcinoma that have progressed on osimertinib treatment

SATIN

1st line and beyond
Targeted Therapy, radiotherapy

Safety of TKI concurrent with cranial radiotherapy in NSCLC patients; the SATIN platform trial

SIRP-alfa

3rd and beyond
Imaging

An open label Phase I PET imaging study to investigate the bio- distribution and tumor uptake of [89Zr]Zr-BI 765063 in patients with head and neck squamous cell carcinoma, non-small cell lung cancer or melanoma who are also treated with ezabenlimab

SCLC

ADRIATIC

1st line
Immunotherapy

A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)

BMS-CA001-050

A Randomized, Open-label Phase 2 Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive stage Small Cell Lung Cancer

Overig

Drug Access Protocol (DAP)

A Dutch National Protocol to Facilitate Patient Access to Novel Anti-cancer Drugs Awaiting Regulatory Approval or Reimbursement

TBPETCT001

Exploring new imaging opportunities using a large axial field of view PET-CT system